Equivalent doses study of nalbuphine and sufentanil for colonoscopy under bispectral index monitoring

Equivalent doses study of nalbuphine and sufentanil for Colonoscopy under Bispectral Index Monitoring

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009184

Enrollment

Unknown

Registered

2016-09-10

Start date

2016-09-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive diseases

Interventions

S:0.1ug/kg sufentanil

N1: 0.1mg/kg nalbuphine

N2:0.15mg/kg nalbuphine

N3:0.2mg/kg nalbuphine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-65 years; (2) BMI (Body Mass Index) 18.5~30 kg/m2; (3) ASA I-III; (4) the duration time of gastroscopy <30min.

Exclusion criteria

Exclusion criteria: history of abnormal anesthesia recovery, ECG:Heart rate(HR)180/110 mmHg and/or diastolic blood pressure (DBP) > 110 mmHg, or BP < 90/60 mmHg, neuromuscular disease, possible or happened difficult airway, Suspected abuse of narcotic analgesics or sedatives,allergy to emulsion or opioid,ECG:Heart rate(HR)<50 times/min.

Countries

China

Contacts

Public ContactWang Xiao

West China Hospital, Sichuan University

1490829116@qq.com+86 18980601549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026